Ipamorelin: The Cleanest Growth Hormone Peptide — Complete 2026 Dosing Guide

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Novo Nordisk in the late 1990s. It acts as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a) — commonly called the ghrelin receptor — primarily in pituitary somatotrophs and hypothalamic neurons.

Activating GHSR-1a stimulates the release of stored GH from pituitary somatotrophs. What sets ipamorelin apart from earlier GHRPs is its pharmacological cleanliness:

• No ACTH/cortisol elevation: Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate the pituitary-adrenal axis. This was definitively established by Raun et al. (1998) using both in vitro pituitary cell assays and in vivo rodent models with equimolar doses [1].
• No prolactin elevation: Prolactin increase from GHRP-2 causes libido reduction and gynecomastia concerns. Ipamorelin avoids this entirely.
• Minimal appetite stimulation: GHRP-6 causes significant acute hunger through ghrelin-mediated hypothalamic NPY stimulation. Ipamorelin's hunger effect is minor by comparison.
• Preserved somatostatin feedback: Ipamorelin works within the natural GH feedback loop. When somatostatin (GH's endogenous inhibitor) is high, ipamorelin's GH-releasing effect is blunted — the body can still regulate GH levels. This prevents the runaway IGF-1 elevation seen with exogenous HGH.

The Pulsatile GH Pattern

After subcutaneous injection, ipamorelin reaches peak plasma concentration at 15-30 minutes, triggering a GH pulse that peaks 30-60 minutes post-injection and returns to baseline within 2-4 hours. This pulsatile pattern closely mirrors natural GH secretion — which is essential for optimal anabolic signaling, fat metabolism, and IGF-1 production without receptor downregulation [4].

Ipamorelin has a solid clinical research foundation spanning foundational pharmacology through human clinical trials.

The Foundational Selectivity Study (Raun et al., 1998)

The defining ipamorelin paper from Novo Nordisk established its selectivity advantage over GHRP-2 and GHRP-6. At equimolar doses in rat pituitary cell cultures and in vivo rodent models, ipamorelin produced robust GH stimulation with no detectable ACTH or cortisol elevation — versus significant increases with both comparators. This pharmacological profile set ipamorelin apart from every previous GHRP and remains the foundation for its clinical use today [1].

Clinical Trials for Post-Operative Ileus

Ipamorelin's largest human clinical program was conducted by Helsinn Healthcare for post-operative ileus (POI) — a condition where GI motility is severely impaired following abdominal surgery. Ghrelin receptors in the GI tract regulate motility, and GHSR-1a agonists accelerate GI recovery.

Phase II/III trials (NCT00988520, NCT01328184) demonstrated that ipamorelin significantly reduced time to first bowel movement and hospital length of stay after colonic surgery. While POI differs from anti-aging or body composition applications, these trials validated ipamorelin's human pharmacokinetics, tolerability profile, and dosing parameters in a controlled clinical setting.

GH Pulse and IGF-1 Pharmacodynamics

Multiple human pharmacokinetic studies confirm that 200-300 mcg subcutaneous ipamorelin produces GH peaks of 2-10 ng/mL (versus normal baseline pulses of 0.5-3 ng/mL in adults), with IGF-1 elevation of 15-30% over repeated dosing cycles. Crucially, the pulsatile GH pattern is preserved, and IGF-1 levels remain within or modestly above physiological ranges — avoiding the supraphysiological IGF-1 overshoot that accompanies exogenous GH injection [2,5].

Ipamorelin's clinical value compounds dramatically when combined with a GHRH analog. The mechanism is complementary: ipamorelin stimulates GH release from pituitary somatotrophs by activating ghrelin receptors (GHSR-1a), while GHRH analogs like Mod GRF 1-29 amplify the pituitary's GH synthesis capacity via the GHRH receptor. These pathways act through different second messenger systems and produce synergistic, rather than simply additive, GH pulses — research in human subjects demonstrates 4-10x greater GH peaks from the combination versus either peptide alone [5,6].

The Classic Stack: Ipamorelin + Mod GRF 1-29

Mod GRF 1-29 (often incorrectly called CJC-1295 no-DAC) has a 30-minute half-life similar to ipamorelin. Co-injecting both peptides produces a synchronized, powerful GH pulse that closely mimics natural physiology. Standard doses: 100-200 mcg Mod GRF 1-29 + 200 mcg ipamorelin per injection, 1-3x daily.

Ipamorelin + CJC-1295 DAC

CJC-1295 with Drug Affinity Complex extends the GHRH analog half-life to 7-8 days via albumin binding, enabling once-weekly dosing. Combined with daily ipamorelin, this creates a "GH baseline elevation" from CJC-1295 DAC with ipamorelin-triggered acute pulses layered on top. Weekly CJC-1295 DAC dose: 1-2 mg. This format trades physiological pulsatility for injection convenience — some practitioners prefer it for anti-aging protocols; others prefer pure pulsatile patterns for body composition goals.

Ipamorelin's selectivity translates to an exceptionally clean side effect profile versus older GHRPs:

• Water retention: Mild, most noticeable weeks 2-6. GH increases extracellular water — subcutaneous, not dangerous, and self-resolving as the body adapts to elevated IGF-1.
• Tingling or numbness in extremities: Carpal tunnel-like symptoms from GH-induced fluid shifts around peripheral nerves. More common above 300 mcg per injection. Dose reduction resolves it.
• Headaches: Occasionally in weeks 1-2 as the body adjusts. Usually resolves spontaneously within 7-14 days.
• Injection site reactions: Minor redness or irritation typical of subcutaneous peptide injections. Rotate sites (abdomen, thigh, lateral arm) to minimize this.

What ipamorelin does NOT typically cause (unlike GHRP-2/6): significant cortisol elevation, prolactin increase, acute hunger, or rapid desensitization. Its selectivity profile makes it appropriate for long-duration protocols that would be impractical with less selective GHRPs [1,3].

Ipamorelin's combination of clinical validation, hormonal selectivity, and practical usability makes it the benchmark GHRP in 2026. Whether used alone for sleep and anti-aging optimization or stacked with a GHRH analog for comprehensive body recomposition, it delivers meaningful GH-mediated benefits without the cortisol, prolactin, and hunger downsides that limited older GHRPs.

The key to successful ipamorelin protocols is consistent daily dosing in a fasted state, appropriate injection timing relative to sleep and training, patience for the body composition changes that require weeks to months to manifest, and pairing with a GHRH analog to maximize the synergistic GH pulse amplitude.

For the complete ipamorelin pharmacology profile and comparison to other GHRPs, see the PeptideWiki Ipamorelin Database Page. For the full stack guide, see our CJC-1295 + Ipamorelin Complete Stack Guide.